Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis
Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to c...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2018-07, Vol.98, p.48-58 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | |
| container_start_page | 48 |
| container_title | European journal of cancer (1990) |
| container_volume | 98 |
| creator | Mills, Matthew N. Yang, George Q. Oliver, Daniel E. Liveringhouse, Casey L. Ahmed, Kamran A. Orman, Amber G. Laronga, Christine Hoover, Susan J. Khakpour, Nazanin Costa, Ricardo L.B. Diaz, Roberto |
| description | Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC.
A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan–Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome.
MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p |
| doi_str_mv | 10.1016/j.ejca.2018.04.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2051069843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804918308128</els_id><sourcerecordid>2051069843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-3c0bf450413cabd50c2fe990799b0efdd50afa6e5ee6c4f04899d38dbaceb0d53</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EgvL4ARbISzYJ48RJbMQGlaeEYANry3EmxVUaF9tF6t_jUmDJaqQ7Z640h5BTBjkDVl_Mc5wbnRfARA48B8Z2yISJRmYgqmKXTEBWMhPA5QE5DGEOAI3gsE8OCikaEE09IfhgQ3SDm1lD3zGidzMc0cY1dT2N3i4HpCPOdLSfSFuPOkRq9GjQX9Jr-pxyN-qBTr8jOsUxeqQ3OupWB6Q67dbBhmOy1-sh4MnPPCJvd7ev04fs6eX-cXr9lJmyqmNWGmh7XgFnpdFtV4EpepQSGilbwL5Lie51jRVibXgPXEjZlaJrtcEWuqo8Iufb3qV3HysMUS1sMDgMekS3CqqAikEtBS8TWmxR410IHnu19Hah_VoxUBu9aq42etVGrwKukt50dPbTv2oX2P2d_PpMwNUWwPTlp0WvgrGY3HTWo4mqc_a__i-K142A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2051069843</pqid></control><display><type>article</type><title>Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mills, Matthew N. ; Yang, George Q. ; Oliver, Daniel E. ; Liveringhouse, Casey L. ; Ahmed, Kamran A. ; Orman, Amber G. ; Laronga, Christine ; Hoover, Susan J. ; Khakpour, Nazanin ; Costa, Ricardo L.B. ; Diaz, Roberto</creator><creatorcontrib>Mills, Matthew N. ; Yang, George Q. ; Oliver, Daniel E. ; Liveringhouse, Casey L. ; Ahmed, Kamran A. ; Orman, Amber G. ; Laronga, Christine ; Hoover, Susan J. ; Khakpour, Nazanin ; Costa, Ricardo L.B. ; Diaz, Roberto</creatorcontrib><description><![CDATA[Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC.
A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan–Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome.
MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p < 0.001). TNBC predicted an inferior OS in IDC (p < 0.001) and ILC (p < 0.001). Lumpectomy and radiation (RT) were more common in MedBC (51.7%) and ACC (51.5%) and less common in MBC (33.1%) and ILC (25.4%), when compared to IDC (42.5%, p < 0.001). TNBC patients with MBC (HR 1.39, p < 0.001), MedBC (HR 0.42, p < 0.001) and ACC (HR 0.32, p = 0.003) differed significantly in OS when compared to IDC.
Our results indicate that histologic heterogeneity in TNBC significantly informs patient outcomes and thus, has the potential to aid in the development of optimum personalised treatments.
•Proportion and prognostic value of triple negativity varies by histology.•Treatment trends vary significantly by histology within triple negative breast cancer (TNBC).•Within TNBC, histology informs overall survival.•Prognostic factors associated with overall survival vary by histology within TNBC.]]></description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2018.04.011</identifier><identifier>PMID: 29870876</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenoid cystic breast cancer ; Adult ; Aged ; Apocrine breast cancer ; Breast ; Breast neoplasms ; Carcinoma, Adenoid Cystic - pathology ; Carcinoma, Adenoid Cystic - therapy ; Carcinoma, Ductal, Breast - parasitology ; Carcinoma, Ductal, Breast - therapy ; Carcinoma, Lobular - pathology ; Carcinoma, Lobular - therapy ; Databases, Factual - statistics & numerical data ; Female ; Humans ; Invasive ductal carcinoma ; Invasive lobular carcinoma ; Kaplan-Meier Estimate ; Medullary breast cancer ; Metaplastic breast cancer ; Middle Aged ; Neoplasm Staging ; Prognosis ; Triple negative breast neoplasms ; Triple Negative Breast Neoplasms - pathology ; Triple Negative Breast Neoplasms - therapy ; United States</subject><ispartof>European journal of cancer (1990), 2018-07, Vol.98, p.48-58</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-3c0bf450413cabd50c2fe990799b0efdd50afa6e5ee6c4f04899d38dbaceb0d53</citedby><cites>FETCH-LOGICAL-c356t-3c0bf450413cabd50c2fe990799b0efdd50afa6e5ee6c4f04899d38dbaceb0d53</cites><orcidid>0000-0003-3331-1529 ; 0000-0002-3303-3234</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804918308128$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29870876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mills, Matthew N.</creatorcontrib><creatorcontrib>Yang, George Q.</creatorcontrib><creatorcontrib>Oliver, Daniel E.</creatorcontrib><creatorcontrib>Liveringhouse, Casey L.</creatorcontrib><creatorcontrib>Ahmed, Kamran A.</creatorcontrib><creatorcontrib>Orman, Amber G.</creatorcontrib><creatorcontrib>Laronga, Christine</creatorcontrib><creatorcontrib>Hoover, Susan J.</creatorcontrib><creatorcontrib>Khakpour, Nazanin</creatorcontrib><creatorcontrib>Costa, Ricardo L.B.</creatorcontrib><creatorcontrib>Diaz, Roberto</creatorcontrib><title>Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description><![CDATA[Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC.
A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan–Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome.
MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p < 0.001). TNBC predicted an inferior OS in IDC (p < 0.001) and ILC (p < 0.001). Lumpectomy and radiation (RT) were more common in MedBC (51.7%) and ACC (51.5%) and less common in MBC (33.1%) and ILC (25.4%), when compared to IDC (42.5%, p < 0.001). TNBC patients with MBC (HR 1.39, p < 0.001), MedBC (HR 0.42, p < 0.001) and ACC (HR 0.32, p = 0.003) differed significantly in OS when compared to IDC.
Our results indicate that histologic heterogeneity in TNBC significantly informs patient outcomes and thus, has the potential to aid in the development of optimum personalised treatments.
•Proportion and prognostic value of triple negativity varies by histology.•Treatment trends vary significantly by histology within triple negative breast cancer (TNBC).•Within TNBC, histology informs overall survival.•Prognostic factors associated with overall survival vary by histology within TNBC.]]></description><subject>Adenoid cystic breast cancer</subject><subject>Adult</subject><subject>Aged</subject><subject>Apocrine breast cancer</subject><subject>Breast</subject><subject>Breast neoplasms</subject><subject>Carcinoma, Adenoid Cystic - pathology</subject><subject>Carcinoma, Adenoid Cystic - therapy</subject><subject>Carcinoma, Ductal, Breast - parasitology</subject><subject>Carcinoma, Ductal, Breast - therapy</subject><subject>Carcinoma, Lobular - pathology</subject><subject>Carcinoma, Lobular - therapy</subject><subject>Databases, Factual - statistics & numerical data</subject><subject>Female</subject><subject>Humans</subject><subject>Invasive ductal carcinoma</subject><subject>Invasive lobular carcinoma</subject><subject>Kaplan-Meier Estimate</subject><subject>Medullary breast cancer</subject><subject>Metaplastic breast cancer</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Triple negative breast neoplasms</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Triple Negative Breast Neoplasms - therapy</subject><subject>United States</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EgvL4ARbISzYJ48RJbMQGlaeEYANry3EmxVUaF9tF6t_jUmDJaqQ7Z640h5BTBjkDVl_Mc5wbnRfARA48B8Z2yISJRmYgqmKXTEBWMhPA5QE5DGEOAI3gsE8OCikaEE09IfhgQ3SDm1lD3zGidzMc0cY1dT2N3i4HpCPOdLSfSFuPOkRq9GjQX9Jr-pxyN-qBTr8jOsUxeqQ3OupWB6Q67dbBhmOy1-sh4MnPPCJvd7ev04fs6eX-cXr9lJmyqmNWGmh7XgFnpdFtV4EpepQSGilbwL5Lie51jRVibXgPXEjZlaJrtcEWuqo8Iufb3qV3HysMUS1sMDgMekS3CqqAikEtBS8TWmxR410IHnu19Hah_VoxUBu9aq42etVGrwKukt50dPbTv2oX2P2d_PpMwNUWwPTlp0WvgrGY3HTWo4mqc_a__i-K142A</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Mills, Matthew N.</creator><creator>Yang, George Q.</creator><creator>Oliver, Daniel E.</creator><creator>Liveringhouse, Casey L.</creator><creator>Ahmed, Kamran A.</creator><creator>Orman, Amber G.</creator><creator>Laronga, Christine</creator><creator>Hoover, Susan J.</creator><creator>Khakpour, Nazanin</creator><creator>Costa, Ricardo L.B.</creator><creator>Diaz, Roberto</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3331-1529</orcidid><orcidid>https://orcid.org/0000-0002-3303-3234</orcidid></search><sort><creationdate>201807</creationdate><title>Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis</title><author>Mills, Matthew N. ; Yang, George Q. ; Oliver, Daniel E. ; Liveringhouse, Casey L. ; Ahmed, Kamran A. ; Orman, Amber G. ; Laronga, Christine ; Hoover, Susan J. ; Khakpour, Nazanin ; Costa, Ricardo L.B. ; Diaz, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-3c0bf450413cabd50c2fe990799b0efdd50afa6e5ee6c4f04899d38dbaceb0d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenoid cystic breast cancer</topic><topic>Adult</topic><topic>Aged</topic><topic>Apocrine breast cancer</topic><topic>Breast</topic><topic>Breast neoplasms</topic><topic>Carcinoma, Adenoid Cystic - pathology</topic><topic>Carcinoma, Adenoid Cystic - therapy</topic><topic>Carcinoma, Ductal, Breast - parasitology</topic><topic>Carcinoma, Ductal, Breast - therapy</topic><topic>Carcinoma, Lobular - pathology</topic><topic>Carcinoma, Lobular - therapy</topic><topic>Databases, Factual - statistics & numerical data</topic><topic>Female</topic><topic>Humans</topic><topic>Invasive ductal carcinoma</topic><topic>Invasive lobular carcinoma</topic><topic>Kaplan-Meier Estimate</topic><topic>Medullary breast cancer</topic><topic>Metaplastic breast cancer</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Triple negative breast neoplasms</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Triple Negative Breast Neoplasms - therapy</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mills, Matthew N.</creatorcontrib><creatorcontrib>Yang, George Q.</creatorcontrib><creatorcontrib>Oliver, Daniel E.</creatorcontrib><creatorcontrib>Liveringhouse, Casey L.</creatorcontrib><creatorcontrib>Ahmed, Kamran A.</creatorcontrib><creatorcontrib>Orman, Amber G.</creatorcontrib><creatorcontrib>Laronga, Christine</creatorcontrib><creatorcontrib>Hoover, Susan J.</creatorcontrib><creatorcontrib>Khakpour, Nazanin</creatorcontrib><creatorcontrib>Costa, Ricardo L.B.</creatorcontrib><creatorcontrib>Diaz, Roberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mills, Matthew N.</au><au>Yang, George Q.</au><au>Oliver, Daniel E.</au><au>Liveringhouse, Casey L.</au><au>Ahmed, Kamran A.</au><au>Orman, Amber G.</au><au>Laronga, Christine</au><au>Hoover, Susan J.</au><au>Khakpour, Nazanin</au><au>Costa, Ricardo L.B.</au><au>Diaz, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2018-07</date><risdate>2018</risdate><volume>98</volume><spage>48</spage><epage>58</epage><pages>48-58</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract><![CDATA[Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC.
A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan–Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome.
MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p < 0.001). TNBC predicted an inferior OS in IDC (p < 0.001) and ILC (p < 0.001). Lumpectomy and radiation (RT) were more common in MedBC (51.7%) and ACC (51.5%) and less common in MBC (33.1%) and ILC (25.4%), when compared to IDC (42.5%, p < 0.001). TNBC patients with MBC (HR 1.39, p < 0.001), MedBC (HR 0.42, p < 0.001) and ACC (HR 0.32, p = 0.003) differed significantly in OS when compared to IDC.
Our results indicate that histologic heterogeneity in TNBC significantly informs patient outcomes and thus, has the potential to aid in the development of optimum personalised treatments.
•Proportion and prognostic value of triple negativity varies by histology.•Treatment trends vary significantly by histology within triple negative breast cancer (TNBC).•Within TNBC, histology informs overall survival.•Prognostic factors associated with overall survival vary by histology within TNBC.]]></abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29870876</pmid><doi>10.1016/j.ejca.2018.04.011</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3331-1529</orcidid><orcidid>https://orcid.org/0000-0002-3303-3234</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2018-07, Vol.98, p.48-58 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2051069843 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenoid cystic breast cancer Adult Aged Apocrine breast cancer Breast Breast neoplasms Carcinoma, Adenoid Cystic - pathology Carcinoma, Adenoid Cystic - therapy Carcinoma, Ductal, Breast - parasitology Carcinoma, Ductal, Breast - therapy Carcinoma, Lobular - pathology Carcinoma, Lobular - therapy Databases, Factual - statistics & numerical data Female Humans Invasive ductal carcinoma Invasive lobular carcinoma Kaplan-Meier Estimate Medullary breast cancer Metaplastic breast cancer Middle Aged Neoplasm Staging Prognosis Triple negative breast neoplasms Triple Negative Breast Neoplasms - pathology Triple Negative Breast Neoplasms - therapy United States |
| title | Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A04%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histologic%20heterogeneity%20of%20triple%20negative%20breast%20cancer:%20A%20National%20Cancer%20Centre%20Database%20analysis&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Mills,%20Matthew%20N.&rft.date=2018-07&rft.volume=98&rft.spage=48&rft.epage=58&rft.pages=48-58&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2018.04.011&rft_dat=%3Cproquest_cross%3E2051069843%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2051069843&rft_id=info:pmid/29870876&rft_els_id=S0959804918308128&rfr_iscdi=true |